Latest News

This Q&A interview highlights ways to counsel patients regarding the safety of various sunscreens, photoprotection, and UV radiation's impact on skin cancer.

New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.

New data from ENDO 2026 reflect the accompanying reductions in HbA1c, lipids, and other major biomarkers in patients treated with GLP-1 RAs.

New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.

MiniMed 780G improved HbA1c and time in range in real-world diabetes data presented at ENDO 2026, with minimal hypoglycemia risk.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

The FDA has cleared Dexcom's Stelo Glucose Biosensor System for over-the-counter use in children as young as 2 years who do not use insulin.

Teplizumab becomes the first disease-modifying therapy approved for patients recently diagnosed with stage 3 type 1 diabetes.

At the SDPA 2026 Summer Dermatology Conference, Mark Eliason, MD, and Mili Shum, MD, presented a joint session on treating chronic urticaria (CSU).

Octavio Galindo, MD, discusses findings from a prospective Spanish cohort (SENDO) linking high UPF intake to asthma incidence in school-age children.

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

LATITUDE Atlas saw more than 35% of patients receiving zasocitinib 30 mg once daily reaching a PASI100 response at week 16, the primary endpoint.

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

This episode covers recently released data regarding the Dexcom G7 and Eli Lilly’s investigational triple agonist retatrutide from ADA 2026.

This preview of the 2026 SDPA Summer Dermatology Conference highlights different sessions and interviews covered by the HCPLive team.

An APP forum discusses navigating a complex biologic landscape with significant administrative, access, and patient education responsibilities that physicians may encounter less directly.

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Eli Lilly announced FDA approval of a 250 mg every-8-week lebrikizumab maintenance regimen, supported by 32-week ADjoin extension data.

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.

The FDA marked bemotrizinol as first new active ingredient on the over-the-counter (OTC) sunscreen monograph since the 1990s.

Learn what the first-ever CKM syndrome guideline means for screening, treatment, and the connection between heart disease, kidney disease, diabetes, and obesity.

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

At ATS 2026, Robert Wallis, MD, discussed PanTB-HM findings on FEV1 recovery and NAC antimicrobial interactions.